Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial

Abstract Aims/Introduction We compared treatment satisfaction in type 2 diabetes patients taking daily and weekly glucagon‐like peptide‐1 receptor agonists. Materials and Methods The study was a 12‐week, multicenter, open‐label, prospective, randomized, parallel‐group comparison trial. The participa...

Full description

Bibliographic Details
Published in:	Journal of Diabetes Investigation
Main Authors:	Takahiro Takase, Akinobu Nakamura, Chiho Yamamoto, Hiroshi Nomoto, Aika Miya, Midori Dannoura, Kyu Yong Cho, Yoshio Kurihara, Naoki Manda, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi
Format:	Article
Language:	English
Published:	Wiley 2019-05-01
Subjects:	Dulaglutide Treatment satisfaction Type 2 diabetes
Online Access:	https://doi.org/10.1111/jdi.12906

Similar Items

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
by: Takahiro Iijima, et al.
Published: (2023-06-01)

Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients
by: Jhih-Wei Dai, et al.
Published: (2024-11-01)

Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes
by: Yu Su, et al.
Published: (2023-01-01)

Economic evaluation of liraglutide vs dulaglutide or oral semaglutide in patients with type 2 diabetes mellitus: a systematic review
by: Lu Wang, et al.
Published: (2025-08-01)

Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus
by: Juan Du, et al.
Published: (2023-01-01)

Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis
by: Mohammad Amin Karimi, et al.
Published: (2025-05-01)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
by: Thompson AM, et al.
Published: (2016-05-01)

Efficacy and safety of dulaglutide: a novel once-weekly glucagon-like peptide-1 analogue
by: A. S. Pogorelova, et al.
Published: (2018-03-01)

Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open‐Label, Active Comparator Study
by: Li Liu, et al.
Published: (2025-04-01)

Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study
by: Ji Young Seo, et al.
Published: (2023-02-01)

Effects of Dulaglutide in Doxorubicin Induced Renal Toxicity in Rats
by: Hama Said HJ, et al.
Published: (2025-07-01)

Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment
by: Chen S, et al.
Published: (2024-03-01)

Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment [Letter]
by: Panjaitan NSD, et al.
Published: (2024-04-01)

Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment [Response to Letter]
by: Chen S, et al.
Published: (2024-04-01)

Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Worsen after the Administration of Dulaglutide
by: Toshitaka Sawamura, et al.
Published: (2022-02-01)

Dulaglutide treatment reverses depression‐like behavior and hippocampal metabolomic homeostasis in mice exposed to chronic mild stress
by: Man Jin, et al.
Published: (2024-03-01)

Improving glycemic control: transitioning from dulaglutide to tirzepatide in patients with type 2 diabetes undergoing hemodialysis
by: Emiko Otsuka, et al.
Published: (2024-05-01)

The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults [version 2; peer review: 2 approved]
by: Sharon Lechtig-Wassermann, et al.
Published: (2023-12-01)

An observational study evaluating effectiveness and therapeutic adherence in patients with Type 2 Diabetes initiating dulaglutide vs. subcutaneous semaglutide in Spain
by: Santiago Tofé, et al.
Published: (2021-03-01)

Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes
by: Keith C. Ferdinand, et al.
Published: (2023-03-01)

Once weekly dulaglutide therapy in type 2 diabetic subjects, real-world evidence from a tertiary care diabetes center in India
by: Jasjeet S Wasir, et al.
Published: (2018-01-01)

Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature
by: Benedetta Sonego, et al.
Published: (2023-06-01)

Achieving the composite end‐point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once‐weekly dulaglutide in Chinese patients with type 2 diabetes: A post‐hoc analysis
by: Xinhua Xiao, et al.
Published: (2020-05-01)

Efficacy and Safety of Injectable Dulaglutide 1.5 mg Among Type 2 Diabetes Patients in Clinics at King Saud Medical City, Riyadh, Saudi Arabia
by: Mashael Saad Albargawi, et al.
Published: (2024-05-01)

The role of dulaglutide in the treatment of alcohol use disorder: a case report
by: Olivia Hill, et al.
Published: (2025-05-01)

Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study
by: Jeonghee Han, et al.
Published: (2024-05-01)

Efficacy of dulaglutide: an evidence-based review of its potential indications
by: E. V. Biryukova, et al.
Published: (2021-05-01)

Effects of dulaglutide combined with insulin degludec on glucose fluctuations and appetite in type 2 diabetes
by: Jinxin Huang, et al.
Published: (2023-05-01)

Long‐Term Activation of Glucagon‐like peptide‐1 receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes
by: Saiyang Xie, et al.
Published: (2022-10-01)

Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study
by: Hisayuki Katsuyama, et al.
Published: (2023-03-01)

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
by: Marina V. Shestakova, et al.
Published: (2017-08-01)

Transformative weight loss with Dulaglutide: A case report of success in a challenging patient profile of an ex‐sumo wrestler
by: Sohail Bade, et al.
Published: (2024-09-01)

Comparative efficacy and safety of weekly dulaglutide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials
by: Hazem Ayesh, et al.
Published: (2024-06-01)

Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study
by: Yuki Oe, et al.
Published: (2022-01-01)

Dulaglutide Ameliorates Intrauterine Adhesion by Suppressing Inflammation and Epithelial–Mesenchymal Transition via Inhibiting the TGF-β/Smad2 Signaling Pathway
by: Yifan Wang, et al.
Published: (2023-07-01)

Cardiovascular Outcomes of Semaglutide vs Dulaglutide in Nonobese Type II Diabetes Patients With HFpEF
by: Patrick A. Kwaah, MBChB, et al.
Published: (2025-07-01)

An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis
by: Daisuke Ugamura, et al.
Published: (2022-06-01)

Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus
by: Dandan Xie, et al.
Published: (2022-10-01)

Hypersensitivity to glucagon‐like peptide‐1 receptor agonists: A case of delayed urticaria‐like rash to dulaglutide and literature review
by: Leonardo Bianchi, et al.
Published: (2024-03-01)

Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)
by: Sho Furusawa, et al.
Published: (2024-06-01)